Comparing the current results to its competitors, Vaxcyte Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 3.1 %, recorded in the same quarter.
Vaxcyte Inc 's Comment on Competition and Industry Peers
The vaccine market is primarily dominated by multinational pharmaceutical companies including Pfizer, Merck, GSK, and Sanofi, which have developed and introduced most new vaccines globally. In the pneumococcal vaccine segment, Pfizer, Merck, and GSK hold the majority of market share and sales. The development of Group A Strep vaccines was inactive for over 30 years until the FDA lifted a ban in 2005. Current development efforts in this area include programs at the GSK Vaccines Institute for Global Health and Moderna. Competitors identified in company filings include GSK, Merck, Moderna, Pfizer, and Sanofi.
August 6, 2024
Vaxcyte Reports Q2 2024 Financial Results with Promising Developments in Vaccine ResearchIn its latest financial announcement, Vaxcyte, Inc. has released its second quarter results for 2024, detailing key aspects of its performance and ongoing research initiatives. The company reported continued investment in its pipeline of vaccines, particularly focusing on VAX-31 and VAX-24, both of which aim to address significant public health challenges.Vaxcyte is currently conducting the VAX-31 Phase 1/2 study, which is set to provide topline data on safety, tolerability, and immunogenicity this coming September 2024. The preliminary outcomes from this study will be critical in determining the progression of VAX-31, ...
Biontech SE's business model focuses on the development and commercialization of novel mRNA-based immunotherapies for various diseases, including cancer.
Glaxosmithkline Plc's business model focuses on researching, developing, manufacturing, and marketing innovative healthcare products and medicines globally.
Immunitybio Inc operates on a business model that focuses on developing and commercializing innovative immunotherapies and vaccines to address various diseases and medical conditions. They aim to use their broad scientific expertise, technology platforms, and strategic partnerships to advance their products and improve patient outcomes in healthcare.
Molecular Partners Ag is a biotechnology company that operates on an innovative business model focused on the development of therapeutic drugs. The company utilizes its proprietary DARPin technology platform to create a pipeline of potential treatments for various diseases. Molecular Partners Ag primarily collaborates with strategic partners, including pharmaceutical companies, to advance its drug candidates through preclinical and clinical development stages.
Sources:
Vaxcyte Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Vaxcyte Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
